SEC Form 4 · accession 0000899243-15-005031
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald K Stern
Director
Period of report
Sep 17, 2015
Accepted (ET)
Sep 18, 2015 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $17.68 | Sep 17, 2015 | A | 31,182 | A | — | Sep 17, 2025 | Common Stock | 31,182 | 31,182 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F2The 31,182 shares of common stock underlying this option will vest in equal one-third increments on September 17, 2016, September 17, 2017 and September 17, 2018.